Comparison of Serum Levels of HSP70 and CA125 in Patients with Epithelial Ovarian Cancer and Patients with Benign Ovarian Masses

Document Type : Original Article

Authors

1 Professor, Department of Obstetrics and Gynecology, Ovulation Dysfunction Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Associate Professor, Department of Obstetrics and Gynecology, Ovulation Dysfunction Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Resident of Obstetrics and Gynecology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Associate Professor, Department of Cytopathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Assistant Professor, Department of Biostatistics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Introduction: Ovarian cancer is one of the most common gynecological malignancies with high mortality rate. This high mortality rate may be due to delay in diagnosis. Using tumor-specific markers that are sensitive in the early stages of cancer is very effective to improve results of therapy. The aim of this study was evaluation of the diagnostic value of serum levels of Heat-shock protein 70 and CA125 in patients with epithelial ovarian tumors.
Methods: This analytical study was conducted on 37 patients with epithelial ovarian cancer and 35 patients with benign ovarian masses in 2011-2012. Blood samples were taken from all patients before the surgery. Patients with ovarian cancer underwent cytoreductive surgery and tumor staging. Also, patients with benign ovarian masses underwent cystectomy or oophorectomy. Serum levels of HSP70 and CA125 were measured by ELISA and RIA, respectively. Finally, HSP70 and CA125 levels were compared before surgery between two groups. Data were analyzed by SPSS software version 16 and Fisher, chi-square, t-student, Mann-Whitney, and ANOVA tests. P value less than 0.05 was considered significant.
Results: Mean age of patients with malignant ovarian cancer was significantly higher than the benign ovarian masses group (p<0.001). Pain was the most prevalent symptom in 62.5% of cases in both groups. Mean levels of CA125 and HSP70 were respectively 672.95±470.55 and 0.859±0.461 in patients with ovarian cancer. The mean levels of CA125 and HSP70 in epithelial ovarian cancer was significantly higher than benign ovarian masses group (p=0.025 and p=0.001, respectively).
Conclusion: HSP70 along with CA125 can be useful for early detection of malignant ovarian cancers.

Keywords

References

  1. Calderwood SK, Ciocca DR. Heat shock proteins: stress proteins with Janus-like properties in cancer. Int J Hyperthermia 2008 Feb;24(1):31-9.
  2. Cohen M, Dromard M, Petignat P. Heat shock proteins in ovarian cancer: a potential target for therapy. Gynecol Oncol 2010 Oct;119(1):164-6.
  3. Chow SN, Chen RJ, Chen CH, Chang TC, Chen LC, Lee WJ, et al. Analysis of protein profiles in human epithelial ovarian cancer tissues by proteomic technology. Eur J Gynaecol Oncol 2010;31(1):55-62.
  4. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, et al. From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer. Int J Cancer 2006 Apr 1;118(7):1750-8.
  5. Fujita Y, Nakanishi T, Miyamoto Y, Hiramatsu M, Mabuchi H, Miyamoto A, et al. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett 2008 May 18;263(2):280-90.
  6. Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszyński T, Zamłyński J, Stołtny P, et al. Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma. Int J Gynecol Cancer 2009 Dec;19(9):1516-20.
  7. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007 Jan;81(1):15-27.
  8. Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27- kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol 2002 Aug;128(8):426-32.
  9. Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995 Dec;1(12):1603-9.
  10. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implication. Cell Stress Chaperones 2005 Summer;10(2):86-103.
  11. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL . Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993 Apr 7;85(7):570-4.
  12. Elpek GO, Karaveli S, Simsek T, Keles N, Aksoy NH. Expression of heat-shock proteins hsp27, hsp70 and hsp90 in malignant epithelial tumour of the ovaries. APMIS 2003 Apr;111(4):523-30.

Files

Share

How to cite

Statistics